Abstract: The present disclosure provides compositions for targeting neutrophil extracellular traps for diagnostic and therapeutic purposes (e.g., for treating inflammation in conditions or diseases associated with accumulation of neutrophil extracellular traps in a subject in need thereof).

Abstract: Compounds and methods for targeted immune system delivery are disclosed. Pharmaceutical compositions including the disclosed compounds and a pharmaceutically acceptable excipient are also disclosed. Methods of targeted delivery to an antigen-presenting cell, and methods of treating or preventing a disease or condition susceptible to treatment by immunomodulation are disclosed.

Abstract: Provided is a co-polymer of formula A-L-D, or a pharmaceutically acceptable salt thereof, wherein A is a linear, branched or dendritic polyamine; D is a lipid; and L is a linker comprising a water soluble polymer; wherein L is connected to A at a first end through a first covalent bond and connected to D at a second end through a second covalent bond.

Abstract: Nanoparticle compositions and pharmaceutical compositions for the delivery of a polynucleotide and a hydrophobic pharmaceutical agent to a cell or tissue that overexpresses a protease are provided. Methods of making such compositions and methods of using such composition to treat a condition associated with a cell or tissue that overexpresses a protease are provided as well. Also provided are kits for use in treating a condition associated with a cell or tissue that overexpresses a protease. The compositions, methods, and kits can be used to selectively deliver anti-tumor agents to cancer cells.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.

Abstract: Molecular compositions, nanoparticle compositions, and pharmaceutical compositions of the invention provide for the delivery of a polynucleotide to a hypoxic cell or tissue. The compositions can also be used for the delivery a hydrophobic pharmaceutical agent, either alone or in combination with a polynucleotide, to a hypoxic cell or tissue. Methods of making such compositions and methods of using such composition to treat a condition associated with a hypoxic cell or tissue are provided as well. Also provided are kits for use in treating a condition associated with a hypoxic cell or tissue.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.

Abstract: Compounds and methods for targeted immune system delivery are disclosed. Pharmaceutical compositions including the disclosed compounds and a pharmaceutically acceptable excipient are also disclosed. Methods of targeted delivery to an antigen-presenting cell, and methods of treating or preventing a disease or condition susceptible to treatment by immunomodulation are disclosed.

Abstract: Provided is a co-polymer of formula A-L-D, or a pharmaceutically acceptable salt thereof, wherein A is a linear, branched or dendritic polyamine; D is a lipid; and L is a linker comprising a water soluble polymer; wherein L is connected to A at a first end through a first covalent bond and connected to D at a second end through a second covalent bond.

Abstract: Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.

Abstract: Methods of treating diseases through the intracellular enhancement and synergy of chemo- and radiation-therapies by employing cancer cell-specific on-demand mechanical intracellular impact. The methods, quadrapeutics, combines four clinically validated modalities: encapsulated drugs, colloidal gold nanoparticles (GNPs), near-infrared short laser pulses, and X-rays.

Abstract: Stable nanoparticles comprising poorly soluble drugs are disclosed, as well as methods of making and methods of using such nanoparticles, e.g., as therapeutics and diagnostics.

Abstract: Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.

Abstract: siRNA-conjugated liposomes and micelles, methods of making such conjugates, and methods of using such conjugates, such as for the delivery of siRNA to cells to reduce expression of target polypeptides in such cells, are described.

Abstract: Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.

Abstract: Stable colloid nanoparticles comprising poorly soluble drugs are disclosed, as well as methods of making and methods of using such nanoparticles, e.g., as therapeutics and diagnostics.

Abstract: Disclosed are improved pharmaceutical formulations for the delivery of RNA interference agents, such as antisense RNA, micro-RNA and siRNA. The formulations employ mixed micelles including amphipathic conjugates of the iRNA agents and amphipathic micelle-forming molecules with extended hydrophilic chains. Also disclosed are methods of using the pharmaceutical formulations to increase delivery of an iRNA agent to an intracellular target, and to decrease extracellular nuclease degradation of an iRNA agent in the formulations.

Abstract: Nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids are provided. The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA-containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid/PEG-lipid monolayer envelope and offers simple preparation, high loading capacity, and in vivo stability. The nanoparticles have good in vivo stability and a prolonged blood circulation time and can effectively deliver a gene to a biological target such as a tumor.

Abstract: Mitochondriotropic phospholipid vesicles, i.e., mitochondriotropic liposomes, that comprise a hydrophobized amphiphilic delocalized cation, such as those comprising, e.g., a triphenylphosphonium or a quinolinium moiety, incorporated into the phospholipid membrane of the vesicles, or liposomes, are disclosed. The hydrophobized portion of the amphiphilic delocalized cation, e.g., a fatty acid or other phospholipid derivative, is embedded in the phospholipid membrane of the liposome, and the amphiphilic portion of the cation is exposed on the surface of the liposome. Mitochondriotropic liposomes constitute a mitochondria-targeted drug delivery system, permitting the transport of a high payload of therapeutic water-soluble molecules in their native (i.e., active) state specifically and exclusively to mitochondria in living mammalian cells.